The invention discloses a method for the continuous preparation of n-butyl nitrite with a low content of n-butanol comprising the reaction of n-butanol, an acid and NaNO.sub.2 in a continuous way, in which the n-butanol, an acid and NaNO.sub.2 are mixed in a mixing device which provides for a pressure drop of at least 1 bar; the acid is selected from the group consisting of HCI, H.sub.2SO.sub.4, formic acid, methanesulfonic acid, and mixtures thereof; and the amount of HCI is at least 1.02 molar equivalent based on the molar amount of n-butanol.

The invention discloses a method for the continuous preparation of n-butyl nitrite with a low content of n-butanol comprising the reaction of n-butanol, an acid and NaNO.sub.2 in a continuous way, in which the n-butanol, an acid and NaNO.sub.2 are mixed in a mixing device which provides for a pressure drop of at least 1 bar; the acid is selected from the group consisting of HCI, H.sub.2SO.sub.4, formic acid, methanesulfonic acid, and mixtures thereof; and the amount of HCI is at least 1.02 molar equivalent based on the molar amount of n-butanol.

The invention discloses a method for the continuous preparation of n-butyl nitrite with a low content of n-butanol comprising the reaction of n-butanol, an acid and NaNO.sub.2 in a continuous way, in which the n-butanol, an acid and NaNO.sub.2 are mixed in a mixing device which provides for a pressure drop of at least 1 bar; the acid is selected from the group consisting of HCI, H.sub.2SO.sub.4, formic acid, methanesulfonic acid, and mixtures thereof; and the amount of HCI is at least 1.02 molar equivalent based on the molar amount of n-butanol.

The invention discloses a method for the continuous preparation of n-butyl nitrite with a low content of n-butanol comprising the reaction of n-butanol, an acid and NaNO.sub.2 in a continuous way, in which the n-butanol, an acid and NaNO.sub.2 are mixed in a mixing device which provides for a pressure drop of at least 1 bar; the acid is selected from the group consisting of HCI, H.sub.2SO.sub.4, formic acid, methanesulfonic acid, and mixtures thereof; and the amount of HCI is at least 1.02 molar equivalent based on the molar amount of n-butanol.

The present technology relates to novel cannabinergic nitrate esters and related analogs, process of preparation, pharmaceutical compositions and their methods of use as medicaments, pharmacological tools and/or biomarkers. The novel cannabinergic nitrate ester compounds provide medicaments useful in treating a variety of diseases and medical disorders.

The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.

The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment and/or prophylaxis of glaucoma and ocular hypertension.

The present technology relates to novel cannabinergic nitrate esters and related analogs, process of preparation, pharmaceutical compositions and their methods of use as medicaments, pharmacological tools and/or biomarkers. The novel cannabinergic nitrate ester compounds provide medicaments useful in treating a variety of diseases and medical disorders.

The present technology relates to novel cannabinergic nitrate esters and related analogs, process of preparation, pharmaceutical compositions and their methods of use as medicaments, pharmacological tools and/or biomarkers. The novel cannabinergic nitrate ester compounds provide medicaments useful in treating a variety of diseases and medical disorders.